Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/47570
Title: Impact of left-heart myopathy on mitral valve stenosis assessment and interventional outcomes: an in-silico trial
Authors: van den Acker, Gitte P. H.
DHONT, Sebastiaan 
van Loon, Tim
Churchill, Timothy W.
Timmermans, Frank
Delhaas, Tammo
BERTRAND, Philippe 
Lumens, Joost
Issue Date: 2025
Publisher: OXFORD UNIV PRESS
Source: European heart journal. Digital health,
Status: Early view
Abstract: Aims The shift in mitral stenosis (MS) aetiology from rheumatic to calcific valve disease complicates distinguishing valve-related from myocardial-driven haemodynamic abnormalities. This study examines how left-heart myopathy influences flow velocity-based echocardiographic MS severity assessment and evaluates haemodynamic changes following mitral valve (MV) intervention at rest and during exercise.Methods and results The CircAdapt biophysical model was used to create a virtual cohort with varying MS severity, left ventricular (LV) compliance, and left atrial (LA) function. Mean gradient (MG) was evaluated alongside left-heart pressures at rest and during exercise. To study acute haemodynamic effects of MV intervention, the mitral valve's effective orifice area was restored to 5.9 cm(2). MG showed variation of 1 mmHg attributable to left-heart myopathy. Following virtual MV intervention for clinically significant MS, mean left atrial pressure (mLAP) decreased by 50% in patients with preserved myocardial function but remained elevated in those with LV and LA dysfunction due to persistently elevated LV end-diastolic pressure, resulting in persistently impaired exercise capacity.Conclusion Virtual patient cohorts suggest that MV intervention reduces MG but may not normalize mLAP in patients with impaired LV and LA function. Persistent myocardial dysfunction may limit both symptomatic and exercise capacity improvement, despite successful intervention. As percutaneous treatment options expand, distinguishing myocardial from valve-driven abnormalities is essential for accurate assessment, patient selection, and optimizing outcomes.
Notes: van den Acker, GPH (corresponding author), Maastricht Univ, CARIM Cardiovasc Res Inst Maastricht, Dept Biomed Engn, Univ Singel 40, NL-6229 Maastricht, Netherlands.
gitte.vandenacker@maastrichtuniversity.nl
Keywords: Mitral valve stenosis;CircAdapt;Computational modelling and simulation;Echocardiography;In-silico clinical trial
Document URI: http://hdl.handle.net/1942/47570
e-ISSN: 2634-3916
DOI: 10.1093/ehjdh/ztaf097
ISI #: 001584873400001
Rights: The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.